Artikel ; Online: Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.
Expert review of clinical pharmacology
2024 Band 17, Heft 3, Seite(n) 235–246
Abstract: Introduction: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach.: Areas ... ...
| Abstract | Introduction: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach. Areas covered: Focusing on pharmacological interventions, we discuss the roles of GLP-1 agonists and GLP/GIP agonists in diabetes management and cardiovascular risk reduction. Tirzepatide, a novel medication, is highlighted for its unique mechanism of action. Clinical trials demonstrate its effectiveness in glucose control, weight reduction, and its potential impact on diabetes, obesity, NASH, and cardiovascular risks. Expert opinion: Tirzepatide shows promise in diabetes treatment, offering glucose control and weight loss. It also holds potential for addressing comorbidities. However, cautious use is vital due to potential adverse effects and contraindications, including hypersensitivity reactions, pregnancy, and breastfeeding precautions. This review underscores tirzepatide as a valuable addition to diabetes therapies, with evolving prospects for enhanced patient outcomes as research advances. |
|---|---|
| Mesh-Begriff(e) | Female ; Pregnancy ; Humans ; Glycemic Control ; Blood Glucose ; Diabetes Mellitus/drug therapy ; Gastric Inhibitory Polypeptide ; Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents/adverse effects ; Glucagon-Like Peptide-2 Receptor |
| Chemische Substanzen | tirzepatide (OYN3CCI6QE) ; Blood Glucose ; Gastric Inhibitory Polypeptide (59392-49-3) ; Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; Glucagon-Like Peptide-2 Receptor |
| Sprache | Englisch |
| Erscheinungsdatum | 2024-01-31 |
| Erscheinungsland | England |
| Dokumenttyp | Journal Article ; Review |
| ISSN | 1751-2441 |
| ISSN (online) | 1751-2441 |
| DOI | 10.1080/17512433.2024.2310070 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.
Fernleihe an ZB MED
Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.